Chemed president and CEO Kevin McNamara sells $1.08 million in stock

Chemed Corp's CEO, Kevin McNamara, divested himself of $1,082,320 worth of the company's stock on August 21, 2026. The sales involved 2,000 shares, with prices fluctuating between $539.62 and $542.53, averaging at $541.16 per share. Post-sales, McNamara personally owns 70,418 shares of Chemed. The CEO also holds the position of director for the company.

This insider sale took place as Chemed's stock hovered near its 52-week peak of $557, delivering an impressive 27% return year-to-date. Despite the stock being deemed overvalued compared to its Fair Value, the healthcare services provider has increased its dividend for 17 consecutive years. InvestingPro provides a comprehensive analysis of such metrics and exclusive Pro Research Reports for CHE and over 1,400 other US stocks.

Chemed Corporation recently reported robust earnings and revenue in its second quarter, exceeding Wall Street's projections. The company reported adjusted earnings of $6.06 per share, surpassing analysts' estimate of $5.60 per share. Revenue for the quarter was $673.25 million, also outpacing the projected $665.04 million. This success was credited to the strong performance of its hospice unit, VITAS, and steady results from Roto-Rooter.

Chemed's earnings rose 41.9% year-over-year, demonstrating improved operating leverage. The company raised its financial outlook following these impressive results.